

Publikationen Peter Riederer (2016 – 2024)

2016

1174) Grünblatt E, Riederer P; ,Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease. *J Neural Transm (Vienna)*. 2016 Feb;123(2):83-90. doi: 10.1007/s00702-014-1320-1. Epub 2014 Oct 9.

1175) Naoi M, Riederer P, Maruyama W.; Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. *J Neural Transm (Vienna)*. 2016 Feb;123(2):91-106. doi: 10.1007/s00702-014-1362-4. Epub 2015 Jan 22.

1176) Ibragić S, Matak I, Dračić A, Smajlović A, Muminović M, Proft F, Sofić E, Lacković Z, Riederer P. Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats. *Neurosci Lett*. 2016 Mar 23;617:213-7. doi: 10.1016/j.neulet.2016.02.020. Epub 2016 Feb 11. PubMed PMID: 26876447.

1177) Plum S, Steinbach S, Attems J, Keers S, Riederer P, Gerlach M, May C, Marcus K. Proteomic characterization of neuromelanin granules isolated from human substantia nigra by laser-microdissection. *Sci Rep*. 2016 Nov 14;6:37139. doi: 10.1038/srep37139. PubMed PMID: 27841354; PubMed Central PMCID: PMC5107900.

1178) Schmitt A, Martins-de-Souza D, Akbarian S, Cassoli JS, Ehrenreich H, Fischer A, Fonteh A, Gattaz WF, Gawlik M, Gerlach M, Grünblatt E, Halene T, Hasan A, Hashimoto K, Kim YK, Kirchner SK, Kornhuber J, Kraus TFJ, Malchow B, Nascimento JM, Rossner M, Schwarz M, Steiner J, Talib L, Thibaut F, Riederer P, Falkai P; Members of the WFSBP Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. *World J Biol Psychiatry*. 2017 Aug;18(5):330-356. doi: 10.1080/15622975.2016.1224929. Epub 2016 Oct 26. PubMed PMID: 27782767.

1179) Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grünblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Ströhle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. *World J Biol Psychiatry*. 2017 Apr;18(3):162-214. doi: 10.1080/15622975.2016.1190867. Epub 2016 Jul 15. Review. PubMed PMID: 27419272; PubMed Central PMCID: PMC5341771.

1180) Bandelow B, Baldwin D, Abelli M, Altamura C, Dell'Osso B, Domschke K, Fineberg NA, Grünblatt E, Jarema M, Maron E, Nutt D, Pini S, Vaghi MM, Wichniak A, Zai G, Riederer P. Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics. *World J Biol Psychiatry*. 2016 Aug;17(5):321-65. doi: 10.1080/15622975.2016.1181783. Epub 2016 Jul 12. PubMed PMID: 27403679.

1181) Schmitt A, Rujescu D, Gawlik M, Hasan A, Hashimoto K, Iceta S, Jarema M, Kambeitz J, Kasper S, Keeser D, Kornhuber J, Koutsouleris N, Lanzenberger R, Malchow B, Saoud M, Spies M, Stöber G, Thibaut F, Riederer P, Falkai P; WFSBP Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on

Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. *World J Biol Psychiatry*. 2016 Sep;17(6):406-28. doi: 10.1080/15622975.2016.1183043. Epub 2016 Jun 17. PubMed PMID: 27311987.

1182) Müller T, Baas H, Kassubek J, Riederer P, Urban PP, Schrader C, Reichmann H, Woitalla D, Gerlach M. Laboratory assessments in the course of Parkinson's disease: a clinician's perspective. *J Neural Transm (Vienna)*. 2016 Jan;123(1):65-71. doi: 10.1007/s00702-015-1481-6. Epub 2015 Nov 14. Review. PubMed PMID: 26573521.

1183) Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. *J Neural Transm (Vienna)*. 2016 Feb;123(2):91-106. doi: 10.1007/s00702-014-1362-4. Epub 2015 Jan 22. Review. PubMed PMID: 25604428.

1184) Grünblatt E, Riederer P. Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease. *J Neural Transm (Vienna)*. 2016 Feb;123(2):83-90. doi: 10.1007/s00702-014-1320-1. Epub 2014 Oct 9. Review. PubMed PMID: 25298080.

2017

1185) Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, Gründer G, Haen E, Baumann P, Bergemann N, Clement HW, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud-Sirot E, Laux G, Messer T, Mössner R, Müller MJ, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Silva Gracia M, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zurek G, Hiemke C. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians(). *World J Biol Psychiatry*. 2018 Mar 1:1-13. doi: 10.1080/15622975.2018.1439595. [Epub ahead of print] PubMed PMID: 29493375.

1186) Grünblatt E, Ruder J, Monoranu CM, Riederer P, Youdim MB, Mandel SA. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra. *Neurotox Res*. 2017 Dec 7. doi: 10.1007/s12640-017-9843-5. [Epub ahead of print] PubMed PMID: 29218503.

1187) Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *World J Biol Psychiatry*. 2017 Oct 27:1-85. doi: 10.1080/15622975.2017.1375556. [Epub ahead of print] PubMed PMID: 29076399.

- 1188) Scholz CJ, Weber H, Jungwirth S, Danielczyk W, Reif A, Tragl KH, Fischer P, Riederer P, Deckert J, Grünblatt E. Explorative results from multistep screening for potential genetic risk loci of Alzheimer's disease in the longitudinal VITA study cohort. *J Neural Transm (Vienna)*. 2018 Jan;125(1):77-87. doi: 10.1007/s00702-017-1796-6. Epub 2017 Oct 12. PubMed PMID: 29027019.
- 1189) Riederer P. Erratum to: Abstracts of the WASAD Congress 2017, in conjunction with the Collaborative Research Centers SFB-TRR 58, Fear, Anxiety, Anxiety Disorders 14-16 September, Würzburg, Germany. *J Neural Transm (Vienna)*. 2017 Oct;124(10):1329. doi: 10.1007/s00702-017-1788-6. PubMed PMID: 28929176.
- 1190) Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, Dermanovic-Dobrota V, Grünblatt E, Jellinger KA, Kamal MA, Kamal W, Leszek J, Sheldrick-Michel TM, Mushtaq G, Meglic B, Natovich R, Pirtosek Z, Rakusa M, Salkovic-Petrisic M, Schmidt R, Schmitt A, Sridhar GR, Vécsei L, Wojszel ZB, Yaman H, Zhang ZG, Cukierman-Yaffe T. The diabetic brain and cognition. *J Neural Transm (Vienna)*. 2017 Nov;124(11):1431-1454. doi: 10.1007/s00702-017-1763-2. Epub 2017 Aug 1. Review. PubMed PMID: 28766040.
- 1191) Bartl J, Palazzesi F, Parrinello M, Hommers L, Riederer P, Walitza S, Grünblatt E. The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro. *Prog Neuropsychopharmacol Biol Psychiatry*. 2017 Oct 3;79(Pt B):281-288. doi: 10.1016/j.pnpbp.2017.07.002. Epub 2017 Jul 8. PubMed PMID: 28690202.
- 1192) Müller T, Riederer P, Grünblatt E. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. *Clin Neuropharmacol*. 2017 Sep/Oct;40(5):208-211. doi: 10.1097/WNF.000000000000233. PubMed PMID: 28682929.
- 1193) Tönges L, Ehret R, Lorrain M, Riederer P, Müngersdorf M. [Epidemiology of Parkinson's Disease and Current Concepts of Outpatient Care in Germany]. *Fortschr Neurol Psychiatr*. 2017 Jun;85(6):329-335. doi: 10.1055/s-0043-103275. Epub 2017 Jun 23. German. PubMed PMID: 28645125.
- 1194) Riederer P. Prof. Dr. Kurt Jellinger: an appreciation. *J Neural Transm (Vienna)*. 2017 Jun;124(6):669-670. doi: 10.1007/s00702-017-1733-8. PubMed PMID: 28508292.
- 1195) Krüger R, Klucken J, Weiss D, Tönges L, Kolber P, Unterecker S, Lorrain M, Baas H, Müller T, Riederer P. Classification of advanced stages of Parkinson's disease: translation into stratified treatments. *J Neural Transm (Vienna)*. 2017 Aug;124(8):1015-1027. doi: 10.1007/s00702-017-1707-x. Epub 2017 Mar 24. Review. PubMed PMID: 28342083; PubMed Central PMCID: PMC5514193.
- 1196) Müller T, Riederer P, Grünblatt E. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. *J Neural Transm (Vienna)*. 2017 Jun;124(6):745-748. doi: 10.1007/s00702-017-1705-z. Epub 2017 Mar 15. PubMed PMID: 28299453.
- 1197) Riederer P, Müller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. *Expert Opin Drug Metab Toxicol*. 2017 Feb;13(2):233-240. doi: 10.1080/17425255.2017.1273901. Epub 2017 Jan 1. Review. PubMed PMID: 27998194.

1198) Schmitt A, Martins-de-Souza D, Akbarian S, Cassoli JS, Ehrenreich H, Fischer A, Fonteh A, Gattaz WF, Gawlik M, Gerlach M, Grünblatt E, Halene T, Hasan A, Hashimoto K, Kim YK, Kirchner SK, Kornhuber J, Kraus TFJ, Malchow B, Nascimento JM, Rossner M, Schwarz M, Steiner J, Talib L, Thibaut F, Riederer P, Falkai P; Members of the WFSBP Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. *World J Biol Psychiatry*. 2017 Aug;18(5):330-356. doi: 10.1080/15622975.2016.1224929. Epub 2016 Oct 26. PubMed PMID: 27782767.

1199) Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grünblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Ströhle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. *World J Biol Psychiatry*. 2017 Apr;18(3):162-214. doi: 10.1080/15622975.2016.1190867. Epub 2016 Jul 15. Review. PubMed PMID: 27419272; PubMed Central PMCID: PMC5341771.

1200) Bartl J, Palazzesi F, Parrinello M, Hommers L, Riederer P, Walitza S, Grünblatt E. The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro. *Prog Neuropsychopharmacol Biol Psychiatry*. 2017 Oct 3;79(Pt B):281-288. doi: 10.1016/j.pnpbp.2017.07.002. Epub 2017 Jul 8. PMID: 28690202

1201) Riederer P, Laux G, Müller T, Gerlach M. Ausgangssituation und Ziele einer Plattform zur Verbesserung der Neuro-/Psychopharmakotherapie in Deutschland. *Psychopharmakotherapie* 24:171 (2017)

1202) Knezovic A, Loncar A, Homolak J, Smailovic U, Osmanovic Barilar J, Ganoci L, Bozina N, Riederer P, Salkovic-Petrusic M. Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease? *J Neural Transm (Vienna)*. 2017 Jun;124(6):695-708. doi: 10.1007/s00702-017-1727-6. Epub 2017 May 3. PubMed PMID: 28470423.

1203) Sheldrick, A., Camara, S., Ilieva, M., Riederer, P., & Michel, T. M. (2017). Brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) levels in post-mortem brain tissue from patients with depression compared to healthy individuals - a proof of concept study. *European psychiatry : the journal of the Association of European Psychiatrists*, 46, 65–71. <https://doi.org/10.1016/j.eurpsy.2017.06.009>

1204) Riederer P, Hoyer S (2017); Störungen der Neurotransmission bei Demenzen. In: Wallesch, Förstl: Demenzen (3. Auflage). Thieme Stuttgart pp 52 - 66

2018

1205) Knezovic A, Barilar JO, Babic A, Bagaric R, Farkas V, Riederer P, Salkovic-Petrusic M. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease. *Neuropharmacology*. 2018 Feb 28. pii: S0028-3908(18)30093-5. doi: 10.1016/j.neuropharm.2018.02.027. [Epub ahead of print] PubMed PMID: 29501615.

1206) Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, Gründer G, Haen E, Baumann P, Bergemann N, Clement HW, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud-Sirot E, Laux G, Messer T, Mössner R, Müller MJ, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Silva Gracia M, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgl R, Zurek G, Hiemke C. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians (). *World J Biol Psychiatry*. 2018 Mar 1:1-13. doi: 10.1080/15622975.2018.1439595. [Epub ahead of print] PubMed PMID: 29493375.

1207) Szökő É, Tábi T, Riederer P, Vécsei L, Magyar K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. *J Neural Transm (Vienna)*. 2018 Feb 7. doi: 10.1007/s00702-018-1853-9. [Epub ahead of print] Review. PubMed PMID: 29417334.

1208) Riederer P, Takahashi R, Hattori N. Toshiharu (Toshi) Nagatsu: an appreciation. *J Neural Transm (Vienna)*. 2018 Jan;125(1):1-2. doi: 10.1007/s00702-017-1826-4. PubMed PMID: 29260324.

1209) Scholz CJ, Weber H, Jungwirth S, Danielczyk W, Reif A, Tragl KH, Fischer P, Riederer P, Deckert J, Grünblatt E. Explorative results from multistep screening for potential genetic risk loci of Alzheimer's disease in the longitudinal VITA study cohort. *J Neural Transm (Vienna)*. 2018 Jan;125(1):77-87. doi: 10.1007/s00702-017-1796-6. Epub 2017 Oct 12. PubMed PMID: 29027019.

1210) Sian-Hülsmann J, Monoranu C.M., Grünblatt E, Riederer P. Neurochemical markers as potential indicators of post-mortem tissue quality. In: Huitinga I, Webster M.J. (ed.) *Handbook of Clinical Neurology, Vol 150 (3rd series) Brain Banking* pp. 119-127, Elsevier B.V. (2018)

1211) Unterecker, Stefan & Hefner, Gudrun & Baumann, Pierre & Gründer, Gerd & Bergemann, Niels & Clement, Hans-Willi & Conca, Univ.-Prof & Deckert, Jürgen & Domschke, Katharina & Eckermann, Gabriel & Egberts, Karin & Gerlach, Manfred & Greiner, Christine & Haen, Ekkehard & Havemann-Reinecke, Ursula & Helmer, Renate & Janssen, Ger & Sirot, Eveline & Laux, Gerd & Hiemke, Christoph. (2018). *Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP*. *Der Nervenarzt*. 90. 10.1007/s00115-018-0643-9.

1212) Pihlstrøm, Lasse & Schottlaender, Lucia & Chelban, Viorica & Houlden, Henry & Al-Sarraj, Safa & Arzberger, Thomas & Bettencourt, Conceição & Bhatia, Kailash & Federoff, Monica & Gelpi, Ellen & Gentleman, Steve & Hardy, John & Holton, Janice & Huitinga, Inge & Levey, Allan & Mann, David & Meissner, Wassilios & Morris, Huw & Consortium, MSA. (2018). LRP10 in α -synucleinopathies. *The Lancet Neurology*. 17. 1033-1034. 10.1016/S1474-4422(18)30407-1.

1213) Strobel, S., Grünblatt, E., Heinsen, H., Riederer, P., Espach, T., Meder, M., & Monoranu, C. M. (2019). Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*, 67(1), 149–157. <https://doi.org/10.3233/JAD-180661>

1214) Shih, J. C., Riederer, P., Maruyama, W., & Naoi, M. (2018). Introduction to the special issue on monoamine oxidase A and B: eternally enigmatic isoenzymes. *Journal of neural transmission (Vienna, Austria : 1996)*, *125*(11), 1517–1518. <https://doi.org/10.1007/s00702-018-1920-2>

1215) Riederer, P., Müller, T. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical–pharmacological aspects. *J Neural Transm* **125**, 1751–1757 (2018). <https://doi.org/10.1007/s00702-018-1876-2>

2019

1216) Riederer, P., Berg, D., Casadei, N., Cheng, F., Classen, J., Dresel, C., Jost, W., Krüger, R., Müller, T., Reichmann, H., Rieß, O., Storch, A., Strobel, S., van Eimeren, T., Völker, H. U., Winkler, J., Winklhofer, K. F., Wüllner, U., Zunke, F., & Monoranu, C. M. (2019). α -Synuclein in Parkinson's disease: causal or bystander?. *Journal of neural transmission (Vienna, Austria : 1996)*, *126*(7), 815–840. <https://doi.org/10.1007/s00702-019-02025-9>

1217) Riederer, P. Anxiety and Stress – Translational Perspectives. *J Neural Transm* **126**, 1115 (2019). <https://doi.org/10.1007/s00702-019-02063-3> Guesteditor: P.Riederer

1218) Leupold, Dieter & Szyk, Lukasz & Stankovic, Goran & Strobel, Sabrina & Völker, Hans-Ullrich & Fleck, Ulrike & Müller, Thomas & Scholz, Matthias & Riederer, Peter & Monoranu, Camelia-Maria. (2019). Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma. *Cells*. 8. 592. 10.3390/cells8060592.

1219) Andrezza, Ana & Laksono, Isabelle & Fernandes, Brisa & Toben, Catherine & Lewczuk, Piotr & Riederer, Peter & Kennedy, Sidney & Kapogiannis, Dimitrios & Thibaut, Florence & Gerlach, Manfred & Gallo, Carla & Kim, Yong-Ku & Grünblatt, Edna & Yatham, Lakshmi & Berk, Michael & Baune, Bernhard. (2019). The World Journal of Biological Psychiatry Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity -a consensus of the Biomarkers Task Force from the WFSBP. *The World Journal of Biological Psychiatry*. 20. 10.1080/15622975.2019.1574024.

1220) Riederer, Peter & Sillaber, Alois & Solomon, Neil & Hirsch, Etienne & Riederer, Christian. (2019). Journal of Neural Transmission: A scientific journal devoted since 1950 to the translation of neuroscience into clinical practice. *Journal of Neural Transmission*. 126. 1-7. 10.1007/s00702-019-01995-0.

1221) Babic Perhoc, A., Osmanovic Barilar, J., Knezovic, A., Farkas, V., Bagaric, R., Svarc, A., Grünblatt, E., Riederer, P., & Salkovic-Petrisic, M. (2019). Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice. *Neuropharmacology*, *148*, 50–67. <https://doi.org/10.1016/j.neuropharm.2018.12.018>

2020

1222) Sian-Hulsmann, J., & Riederer, P. (2020). The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson's disease. *Journal of neural transmission (Vienna, Austria : 1996)*, 127(5), 749–754. <https://doi.org/10.1007/s00702-020-02192-0020>

1223) Riederer P. (2020). Prof. Dr. Moussa B.H. Youdim: an appreciation on the occasion of his 80th birthday. *Journal of neural transmission (Vienna, Austria : 1996)*, 127(2), 117–118. Guesteditor: P.Riederer

1224) Barilar, J. O., Knezovic, A., Perhoc, A. B., Homolak, J., Riederer, P., & Salkovic-Petrisic, M. (2020). Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. *Journal of neural transmission (Vienna, Austria : 1996)*, 127(2), 231–250. <https://doi.org/10.1007/s00702-020-02152-8>

1225) Sian-Hulsmann J, Riederer P. The Odyssey of Alpha-synuclein and Neuroinflammatory Mediators as Potential Candidates in the Aetiology of Parkinson's Disease. *J Exp Neurol*. 2020;1(4): 138-147.

1226) Peter Urban, Bjorn Falkenburger, Wolfgang H. Jost, Gerhard Ransmayr, Peter Riederer, Christian Winkler. Struktur und Efferenzen der Substantia nigra pars compacta beim idiopathischen Parkinson-Syndrom. *Fortschr Neurol Psychiatr* 2020; 88(09): 591-599 DOI: 10.1055/a-1149-9280

1227) Plum, Sarah & Eggers, Britta & Helling, Stefan & Stepath, Markus & Theiss, Carsten & Leite, Renata & Molina, Mariana & Grinberg, Lea & Riederer, Peter & Gerlach, Manfred & May, Caroline & Marcus, Katrin. (2020). Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson's Disease. *Cells*. 9. 2580. 10.3390/cells9122580.

1228) Kösters, Steffen & Rettel, Mandy & Eggers, Britta & Riederer, Peter & Gerlach, Manfred & Savitski, Mikhail & Marcus, Katrin & May, Caroline. (2020). Improved Reproducibility of Protein Detection in Neuromelanin-containing Human Substantia Nigra Tissue enriched by Laser Microdissection. 10.21203/rs.3.rs-78140/v1.

1229) Homolak, Jan & Kodvanj, Ivan & Babić Perhoč, Ana & Virag, Davor & Knezovic, Ana & Osmanovic, Jelena & Riederer, Peter & Salkovic-Petrisic, Melita. (2020). Nitrocellulose Redox Permanganometry (NRP/HistoNRP). 10.1101/2020.06.16.154682v1.

1230) Rabey, Jose & Yarden, Jennifer & Dotan, Nir & Mechlovich, Danit & Riederer, Peter & Youdim, Moussa. (2020). Creation of a gene expression classifier for predicting Parkinson's disease rate of progression. *Journal of Neural Transmission*. 127. 1-8. 10.1007/s00702-020-02194-y.

1231) Riederer, Peter. (2020). Gerald Stern (1930–2018). *Journal of Neural Transmission*. 127. 10.1007/s00702-020-02176-0.

1232) Osmanovic, Jelena & Knezovic, Ana & Babić Perhoč, Ana & Homolak, Jan & Riederer, Peter & Salkovic-Petrisic, Melita. (2020). Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. *Journal of neural transmission* (Vienna, Austria : 1996), 127. 10.1007/s00702-020-02152-8.

1233) Peter Riederer, Würzburg, und Gerd Laux, Soyen . [**15 Jahre „Deutsche Gesellschaft für Experimentelle und Klinische Neuro-Psychopharmako-Therapie“ \(GESENT\)**](#) *Psychopharmakotherapie* 2020;27:141–8.

1234) Riederer, P., ter Meulen, V. Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses. *J Neural Transm* **127**, 1217–1228 (2020). <https://doi.org/10.1007/s00702-020-02230-x>

1235) Tábi, T., Vécsei, L., Youdim, M. B., Riederer, P., & Szökő, É. (2020). Selegiline: a molecule with innovative potential. *Journal of neural transmission* (Vienna, Austria : 1996), 127(5), 831–842. <https://doi.org/10.1007/s00702-019-02082-0>

2021

1236) Riederer, P., Monoranu, C., Strobel, S., Iordache, T., & Sian-Hülsmann, J. (2021). Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease. *Journal of neural transmission* (Vienna, Austria : 1996), 128(10), 1577–1598. <https://doi.org/10.1007/s00702-021-02414-z> IF 3,57

1237) Sian-Hulsmann, J., & Riederer, P. (2021). The Nigral Coup in Parkinson's Disease by α -Synuclein and Its Associated Rebels. *Cells*, 10(3), 598. <https://doi.org/10.3390/cells10030598> IF 4,3

1238) Eap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M. L., de Leon, J., Greiner, C., Howes, O., Kim, E., Lanzenberger, R., Meyer, J. H., Moessner, R., Mulder, H., Müller, D. J., Reis, M., Riederer, P., Ruhe, H. G., ... Hiemke, C. (2021). Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry*, 22(8), 561–628. <https://doi.org/10.1080/15622975.2021.1878427> IF 13,3

1239) Danysz, W., Dekundy, A., Scheschonka, A. and P. Riederer. Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials. *J Neural Transm* **128**, 127–169 (2021). <https://doi.org/10.1007/s00702-021-02306-2> IF 3,57

1240) Cadar, D., Jellinger, K. A., Riederer, P., Strobel, S., Monoranu, C. M., & Tappe, D. (2021). No Metagenomic Evidence of Causative Viral Pathogens in Postencephalitic Parkinsonism Following Encephalitis Lethargica. *Microorganisms*, 9(8), 1716. <https://doi.org/10.3390/microorganisms9081716> IF 3,8

1241) Homolak Jan, Babić Perhoč Ana, Knezovic Ana, Kodvanj Ivan, Virag Davor, Osmanovic Jelena, Riederer Peter, Salkovic-Petrisic Melita (2021) Is galactose a hormetic sugar? Evidence from rat hippocampal redox regulatory network *Mol. Nutrition* **65** (21) DO - 10.1101/2021.03.08.434370 <https://doi.org/10.1002/mnfr.202100400> IF 4,0

1242) Wilfried Kuhn, Thomas Müller, Andrzej Dekundy, Wojciech Danysz, und Peter Riederer Amantadin – klassische Indikationen und das antivirale Potenzial in Zeiten von COVID-19. *Psychopharmakotherapie* 2021;28:260–8

1243) Müller, T., Mueller, B. K., & Riederer, P. (2021). Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. *Cells*, *10*(4), 873. <https://doi.org/10.3390/cells10040873> IF 4,3

1244) Strilciuc, S.; Vécsei, L.; Boering, D.; Pražnikar, A.; Kaut, O.; Riederer, P.; Battistin, L. Safety of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials.(2021) *Pharmaceuticals*, *14*, 1297. <https://doi.org/10.3390/ph14121297>, 2021090446 (doi:10.20944/preprints202109.0446.v2). IF 5,7

1245) Salkovic-Petrisic M., Perhoc A.B., Homolak J., Knezovic A., Osmanovic Barilar J., Riederer P. (2021) Experimental Approach to Alzheimer’s Disease with Emphasis on Insulin Resistance in the Brain. In: Kostrzewa R.M. (eds) *Handbook of Neurotoxicity*. Springer, Cham. https://doi.org/10.1007/978-3-030-71519-9_98-1

1246) Monoranu, Camelia-Maria, [Hartmann, Tim^a](#), [Strobel, Sabrina^b](#), [Heinsen, Helmut^{c,d}](#), [Riederer, Peter^{e,f}](#), [Distel, Luitpold^g](#), [Bohnert, Simone^h](#), ‘Is There Any Evidence of Monocytes Involvement in Alzheimer’s Disease? (2021) A Pilot Study on Human Postmortem Brain’. *J.Alz.Dis.Rep* : 887 – 897

1247) de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., Montreal, L., Antúnez, C., Antonell, A., Tankard, R. M., Bis, J. C., Sims, R., Bellenguez, C., Quintela, I., González-Perez, A., Calero, M.,Riederer,P.,..... Ruiz, A. (2021). Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nature communications*, *12*(1), 3417. <https://doi.org/10.1038/s41467-021-22491-8> IF 14,9

1248) Wenning, Gregor & Riederer, Peter. (2021). Kurt Jellinger, Doyen of international neuropathology. *Journal of Neural Transmission*. 128. 10.1007/s00702-021-02397-x. IF 3,57

1249) Naoi, Makoto & Maruyama, Wakako & Riederer, Peter. (2021). TCM Substances in Neuropsychopharmacotherapy: Basic Aspects with a Focus on Depression. 10.1007/978-3-319-56015-1_394-1. In: ebook on Neuropsychopharmacotherapy; Edts.: P.Riederer, G.Laux, T. Nagatsu and W. Lee; SpringerNature , Heidelberg

1250) Wulf, M., Barkovits-Boeddinghaus, K., Sommer, P., Schork, K., Eisenacher, M., Riederer, P., Gerlach, M., Kösters, S., Eggers, B., Marcus, K. Laser Microdissection-Based Protocol for the LC-MS/MS Analysis of the Proteomic Profile of Neuromelanin Granules. *J. Vis. Exp.* (178), e63289, doi:10.3791/63289 (2021).

1251) Salkovic-Petrisic, M., Perhoc, A.B., Homolak, J., Knezovic, A., Osmanovic Barilar, J., Riederer, P. (2021). Experimental Approach to Alzheimer’s Disease with Emphasis on Insulin

Resistance in the Brain. In: Kostrzewa, R.M. (eds) Handbook of Neurotoxicity. Springer, Cham. https://doi.org/10.1007/978-3-030-71519-9_98-1

1252) Homolak, J., Kodvanj, I., Babic Perhoc, A., Virag, D., Knezovic, A., Osmanovic Barilar, J., Riederer, P., & Salkovic-Petrisic, M. (2021). Nitrocellulose redox permanganometry: A simple method for reductive capacity assessment. *MethodsX*, 9, 101611. <https://doi.org/10.1016/j.mex.2021.101611>

2022

1253) Mueller, J. K., Riederer, P., & Müller, W. E. (2022). Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?. *Pharmacopsychiatry*, 55(1), 7–15. <https://doi.org/10.1055/a-1717-2381>

1254) Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., Holmans, P. A., Boland, A., Damotte, V., van der Lee, S. J., Costa, M. R., Kuulasmaa, T., Yang, Q., de Rojas, I., Bis, J. C., Yaqub, A., ...Riederer P.,..... Lambert, J. C. (2022). New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nature genetics*, 10.1038/s41588-022-01024-z. Advance online publication. <https://doi.org/10.1038/s41588-022-01024-z>

1255) Wulf M, Barkovits K, Schork K, Eisenacher M, Riederer P, Gerlach M, Eggers B, Marcus K. Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes. *J Neural Transm (Vienna)*. 2022 Oct;129(10):1257-1270. doi: 10.1007/s00702-022-02530-4. Epub 2022 Jul 19. PMID: 35852604; PMCID: PMC9468065.

1256) Jost, Wolfgang & Riederer, Peter. (2023). Parkinson's treatment in perspective. Commentary on Levodopa and dopamine agonists in the treatment of Parkinson's disease by Theodore L. Sourkes and Serge Gauthier. 10.1016/B978-0-323-85519-8.00003-1.

1257) Riederer, Peter & Rujescu, Dan. (2023). Commentary on Monoamine oxidase and its inhibitors in relation to antidepressive activity by E. Albert Zeller. 10.1016/B978-0-323-85519-8.00008-0.

1258) Riederer P. (2022) Umbrella- Review zur Serotonin-Theorie der Depression: Kritik aus neurobiochemischer Sicht. *Psychopharmakotherapie* 29: 190-1

1259) Tönges, Lars & Buhmann, Carsten & Klebe, Stephan & Klucken, Jochen & Kwon, Eun & Müller, Thomas & Pedrosa, David & Schröter, Nils & Riederer, Peter & Lingor, Paul. (2022). Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice. *Journal of Neural Transmission*. 129. 10.1007/s00702-022-02498-1.

1260) Gerlach, Manfred & Double, Kay & Riederer, Peter. (2022). Iron-Induced Dopaminergic Cell Death In Vivo as a Model of Parkinson's Disease. In: Handbook of Neurotoxicity; R.M Kostrzewa Ed, 2nd edition;pp

1261) Wulf M, Barkovits K, Schork K, Eisenacher M, Riederer P, Gerlach M, Eggers B, Marcus K. The Proteome of Neuromelanin Granules in Dementia with Lewy Bodies. *Cells*. 2022 Nov 9;11(22):3538. doi: 10.3390/cells11223538. PMID: 36428966; PMCID: PMC9688080.

1262) Riederer P, Laux G, Nagatsu T, Le W, Riederer C, (eds.). *NeuroPsychopharmacotherapy*. Springer, 2022. 4725 p. doi: 10.1007/978-3-030-62059-2

2023

1263) Müller T, Riederer P, Kuhn W. Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome? *Expert Rev Clin Pharmacol*. 2023 Feb 1. doi: 10.1080/17512433.2023.2176301. Epub ahead of print. PMID: 36726198.

1264) Riederer P, Kircher T, Juckel G, Domschke K, Schneider A, Deckert J et al. 45 years German Society of Biological Psychiatry (DGBP). Historical Aspects of the German Society of Biological psychiatry (DGBP) *Journal of Neural Transmission* 2023 May 4. Epub 2023 May 4. doi: 10.1007/s00702-023-02645-2

1265) Gruenblatt E., Homolak J., Babic-Perhoc A., Virag D., Knezovic A., Osmanovic-Barilar J., Riederer P., Walitza S., Tackenberg C., Salkovic-Petrisic M.
From attention-deficit hyperactivity disorder to sporadic Alzheimer's disease – Wnt/mTOR pathways hypothesis
Front. Neurosci., 17:1104985. doi:10.3389/fnins.2023.1104985

1266) Sian-Hulsmann J, Riederer P. The ' α -synucleinopathy syndicate': multiple system atrophy and Parkinson's disease. *Journal of Neural Transmission* 2023 May 25. Epub 2023 May 25. doi: 10.1007/s00702-023-02653-2

1267) Wenzl FA, Mengozzi A, Mohammed SA, Pugliese NR, Mongelli A, Gorica E, Ambrosini S, Riederer P, Fischer P, Hinterberger M, Puspitasari Y, Lüscher TF, Camici GG, Matter CM, Fadini GP, Viridis A, Masi S, Ruschitzka F, Grünblatt E, Paneni F, Costantino S. Circulating Long Noncoding RNA Signatures Associate With Incident Diabetes in Older Adults: A Prospective Analysis From the VITA Cohort Study. *Diabetes Care*. 2023 Jun 1;46(6):1239-1244. doi: 10.2337/dc23-0012. PMID: 37040472; PMCID: PMC10234752.

1268) Nagatsu, T, Nakashima, A, Watanabe, H, Ito, S, Wakamatsu, K, Zucca, FA, Zecca, L, Youdim, M, Wulf, M, Riederer, P & Dijkstra, JM 2023, 'The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease', *Journal of Neural Transmission*, vol. 130, no. 5, pp. 611-625.
<https://doi.org/10.1007/s00702-023-02617-6>

1269) Riederer, P., Nagatsu, T., Youdim, M. B. H., Wulf, M., Dijkstra, J. M., & Sian-Huelsmann, J. (2023). Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease. *Journal of Neural Transmission*, 130(5), 627-646.
<https://doi.org/10.1007/s00702-023-02630-9>

1270) Phokaewvarangkul, Onanong & Bhidayasiri, Roongroj & Garcia-Ruiz, Pedro & Odin, Per & Riederer, Peter & Müller, Thomas. (2023). Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations. *Journal of Neural Transmission*. 1-12. 10.1007/s00702-023-02684-9.

1271) Müller T, Riederer P. The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson's disease. *J Neural Transm (Vienna)*. 2023 Jun 17. doi: 10.1007/s00702-023-02666-x. Epub ahead of print. PMID: 37329350.

1272) Wüllner, U, Borghammer, P, Choe, CU, Csoti, I, Falkenburger, B, Gasser, T, Lingor, P & Riederer, P 2023, 'The heterogeneity of Parkinson's disease', *Journal of Neural Transm*. 130 (6), pp. 827-838. <https://doi.org/10.1007/s00702-023-02635-4>

1273) Lapikova-Bryhinska T, Ministrini S, Puspitasari YM, Kraler S, Mohamed SA, Costantino S, Paneni F, Khetsuriani M, Bengs S, Liberale L, Montecucco F, Krampla W, Riederer P, Hinterberger M, Fischer P, Lüscher TF, Grünblatt E, Akhmedov A, Camici GG. Long non-coding RNAs H19 and NKILA are associated with the risk of death and lacunar stroke in the elderly population. *Eur J Intern Med*. 2023 Nov 17:S0953-6205(23)00411-9. doi: 10.1016/j.ejim.2023.11.013. Epub ahead of print. PMID: 37981527.

1274) Riederer, P., Horowski, R. L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin. *J Neural Transm* **130**, 1323–1335 (2023). <https://doi.org/10.1007/s00702-023-02692-9>

1275) Sian-Hulsmann J, Riederer P. The 'α-synucleinopathy syndicate': multiple system atrophy and Parkinson's disease. *J Neural Transm (Vienna)*. 2023 May 25. doi: 10.1007/s00702-023-02653-2. Epub ahead of print. PMID: 37227594.

2024

1276) Kagerer SM, Awasthi S, Ripke S, et al. Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms. *Alzheimer's Dement*. 2024; 16:e12504. <https://doi.org/10.1002/dad2.12504>

1277) Sian-Hulsmann J, Riederer P. Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view. *J Neural Transm (Vienna)*. 2024 Jan 23. doi: 10.1007/s00702-023-02723-5. Epub ahead of print. PMID: 38261034.

1278) Naoi M, Maruyama W, Shamoto-Nagai M, Riederer P. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's

disease. *J Neural Transm (Vienna)*. 2024 Jan 9. doi: 10.1007/s00702-023-02730-6. Epub ahead of print. PMID: 38196001.